We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Growing European Demand for Mad Cow Test

By HospiMedica staff writers
Posted on 29 Jan 2001
U.S. More...
company Bio-Rad Laboratories (Hercules, CA) has become a leading provider of tests for bovine spongiform encephalopathy (BSE) in Europe. The company reports it has received orders for more than one million enzyme-linked immunosorbent assays (ELISA) for BSE, known as mad cow disease.

Since October 2000, the fear of BSE has spread quickly throughout Europe, as more cattle were found with the disease. Cows with BSE have been discovered in France, Germany, Spain, Portugal, and Italy. On January 1, 2001, the countries of the European Union commenced mandatory testing of all beef livestock over the age of 30 months in order to insure the highest quality and safety of the European food chain. According to media reports, seven million cattle will have to be tested in Europe this year.

Called Platelia, Bio-Rad's test was selected by the European Commission (EC) as one of the three most sensitive BSE tests and is among the three approved in the most recent EC report. Two independent reports commissioned by a directorate of the EC further substantiated Bio-Rad's test as the preferred test for diagnosing BSE in European cattle. The test is in a screening format for use in high throughput environments, providing results in about four hours.

To meet the demand for tests, Bio-Rad has increased manufacturing capabilities at its French facilities and is mobilizing employees around the world to support the scaling up of production. "We have allocated substantial resources to ensure that we can rapidly meet the growing needs for a quick, clear, and accurate test,” said David Schwartz, president and CEO of Bio-Rad.



Related Links:
Bio-Rad

Gold Member
12-Channel ECG
CM1200B
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Patient Monitoring System
AlarmSense
Hybrid Arch Device
Neo EDE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Medical Imaging

view channel
Images from patient T1, who had menstrual cycle–dependent right shoulder pain. (A) Maximum-intensity-projection images show abnormal findings for right diaphragm (arrowhead), bilateral round ligaments, peritoneum around bilateral ovaries, and left fallopian tube. Combined PET/MRI show hyperintense lesion with focal uptake inferior of right diaphragm, indicative of endometriosis (arrowhead, B). Confirmatory laparoscopy demonstrated extensive pelvic disease and implants of right diaphragm (C) that stained intensely positive for FAP (D).  (Image Credit: Schindler P, Brandt J, Bobe S, et al. Initial results of FAPI PET/MRI to assess the extent of endometriosis. J Nucl Med. 2026;67(8):1232–1238. doi:10.2967/jnumed.125.271376)

Targeted PET/MRI Improves Detection and Preoperative Mapping of Endometriosis

Endometriosis is a chronic inflammatory condition in which endometrial-like tissue grows outside the uterus, causing pelvic pain, infertility, and reduced quality of life. Conventional imaging can underestimate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.